Jennifer Crombie, MD, Dana-Farber Cancer Institute, Boston, Massachusetts, discusses results from a real-world study of lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma. Similar to published findings…
Tanya Siddiqi, MD, medical director of lymphoma, City of Hope, Orange County, California, discusses the primary analysis of the TRANSCEND CLL 004 trial. This phase 1/2, single-arm, multicenter…
Sue Heffernan, MN, RN, Clinical Nurse Specialist, Nursing Professional Development, Seattle Children’s Hospital, Seattle WA, discusses the Great Ambassador Program at Seattle Children’s Hospital. References and Resources For…
According to studies presented at the American Urological Association meeting, men with higher cholesterol levels had more than a two-fold greater risk of biochemical relapse after radical prostatectomy…
As presented at ASCO, second-line bevacizumab (Avastin) as monotherapy has been associated with a 28% response rate and an overall survival edge for refractory glioblastoma. Also presented at…
Joseph Schoepf, M.D., Associate Professor of Radiology and Cardiology, Director of Computed Tomography Research, Medical University of South Carolina, discusses the advantages of using CTA. References and Resources…
Mary Wright, MD, Associate Professor & Director, Breast Center, Section of Breast Surgery, Department of Surgery, Tulane University School of Medicine, discusses Tulane’s Breast Cancer Center. References and…
Patrick C. Alguire, MD, FACP, Director, Education and Career Development, American College of Physicians, discusses how physicians can try avoiding burnout. Doctor’s Digest single topic reference guides provide…
Jacob G. Robison, MD, Professor, Vascular Surgery, Medical University of South Carolina, discusses drug-eluting stents. References and Resources Baker M, Uflacker R, Robison JG. Stent graft infection after…
The Federal Aviation Administration has barred pilots and air traffic controllers from using the smoking cessation drug varenicline (Chantix), due to some occurrences of seizures, heart attacks, vision…
A 50-week, placebo-controlled trial shows that combining infliximab and methotrexate provides no extra benefit in treating Crohn’s disease. References and Resources Feagan B. A randomized trial of methotrexate…
Francis G. Spinale, MD, PhD, Associate Professor, Department of Surgery, Medical University of South Carolina, discusses biomarkers in heart failure. References and Resources Spinale FG. Myocardial matrix remodeling…
